Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A two-step dental remineralization agent consisting of **ammonium fluoride solution (AFS, 25,000 ppm F)** applied first, followed by **nano sol calcium fluoride (nano-CaF2, 41,400 ppm F)**, developed by Ivoclar Vivadent AG for treating active buccal white spot lesions (WSLs) in high caries risk adolescents and young adults. It promotes superior caries arrest and remineralization compared to single-step ammonium fluoride varnish (AFV, 7700 ppm F, Fluor Protector S), as shown in a 2025 split-mouth randomized controlled trial where it excelled in quantitative and qualitative assessments of lesion regression[1]. The nano-CaF2 enhances labile fluoride concentration in oral fluid, facilitating apatite formation and reducing dentin permeability[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ammonium fluoride + calcium fluoride.